Summary & Overview
HCPCS Q0083: Chemotherapy Administration, Non-Infusion
HCPCS Level II code Q0083 denotes chemotherapy administration delivered by non-infusion techniques — for example, subcutaneous, intramuscular, or push injections — billed per visit. This procedure-level code is used nationwide to document and bill for the technical service of administering antineoplastic agents when infusion equipment and protocols are not used. Accurate use of this code helps distinguish administration services from drug acquisition and infusion-related services, supporting consistent billing and reporting across settings.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of the clinical context for non-infusion chemotherapy administration, typical sites of service, and an outline of common modifiers and administrative considerations linked to this service line. The publication also provides benchmarking insights, common billing adjustments, and policy considerations relevant to reimbursement and documentation for non-infusion chemotherapy visits. This resource is intended for revenue cycle teams, billing specialists, and clinicians seeking a concise national overview of HCPCS Level II code Q0083 and its administrative implications.
Billing Code Overview
HCPCS Level II code Q0083 represents chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit. This code covers administration of cytotoxic or other antineoplastic agents delivered by non-infusion routes where the visit is billed for the administration procedure rather than drug supply.
Service Type: Chemotherapy administration (non-infusion techniques)
Typical Site of Service: Outpatient clinic, physician office, or ambulatory care setting where injections or push administrations are performed
Clinical & Coding Specifications
Clinical Context
A patient receiving anticancer drugs that are indicated for subcutaneous, intramuscular, or intralesional administration presents to an oncology clinic for a scheduled treatment visit. Typical patients include those receiving supportive agents (e.g., growth factors given subcutaneously), certain chemotherapeutic agents formulated for subcutaneous or intramuscular injection, or short “push” doses administered via syringe into a central port or peripheral IV without prolonged infusion. The clinical workflow: triage and vital signs, medication verification and consent, preparation of the drug by pharmacy or nurse according to sterile technique, verification of the correct route (subcutaneous, intramuscular, or push IV), administration by an authorized oncology nurse or physician, observation for immediate adverse reactions for a short post‑injection period, and documentation of drug, dose, lot number, route, injection site, and patient response in the medical record. Billing uses Q0083 per visit when the chemotherapy is given by a non‑infusion technique and no infusion or infusion‑related CPT is reported for that encounter.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |